When was Frontida BioPharm founded?

Frontida BioPharm was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is Frontida BioPharm located?

Frontida BioPharm is headquartered in Exton, United States. It is registered at Philadelphia, Pennsylvania.

How many employees does Frontida BioPharm have?

As of Mar 31, 2026, the latest employee count at Frontida BioPharm is 57.

Is Frontida BioPharm a funded company?

Frontida BioPharm is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Aug 09, 2016.

When was the latest funding round of Frontida BioPharm?

Frontida BioPharm's latest funding was a $***** Series A round on Aug 09, 2016, with participation from 0 investor.

Where does Frontida BioPharm rank among its competitors?

Frontida BioPharm ranks 14th amongst 338 active competitors, of which 17 are funded. It stands 5th in terms of total funding among its competitors.

Who are the top competitors of Frontida BioPharm?

Frontida BioPharm's top competitors include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group. Among them, Frontida BioPharm secured the most recent funding round in August, 2016.

Frontida BioPharm - 2026 Company Profile, Team, Funding & Competitors

Frontida BioPharm is an acquired company based in Exton (United States), founded in 2016 by Song Li. It operates as a Contract development and manufacturing services for small molecules. Frontida BioPharm has raised $8.35M in funding. The company has 338 active competitors, including 17 funded and 91 that have exited. Its top competitors include companies like Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group.

Company Details

Frontida Biopharm, an affiliate of Frontage Laboratories that is focussed on providing CDMO services for the manufacturing of immediate and controlled release oral solid dose products. It provides the capability to manufacture highly potent active ingredients (HPAIs), combination products and DEA schedules II – V products. It has a patented Duragran granulation process which claims to enhance the drug loading and creates better engineered and cost efficient controlled release products. Along with Frontage Laboratories, the company offers Clinical Trial Materials manufacturing, serialised packaging, warehousing, and stability services.

Website: frontidabiopharm.com/
Registered Address: Philadelphia, Pennsylvania

Key Metrics

Founded Year

2016

Location

Exton, United States

Stage

Acquired

Total Funding

$8.35M in 1 round

Latest Funding Round

Series A, Aug 09, 2016, $*****

Ranked

14^th among 338 active competitors

Employee Count

57 as on Mar 31, 2026

Similar Companies

Concord Biotech & 383 more

Exit Details

Acquired by Adare Pharma Solutions (Dec 01, 2021)

View Frontida BioPharm's full profile

Frontida BioPharm is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
FRONTIDA BIOPHARM, INC. CIN: 810940425 , United States, Active		-	192 (As on Dec 31, 2022)	-

Frontida BioPharm got acquired by Adare Pharma Solutions on Dec 01, 2021.

Click here to take a look at Frontida BioPharm's acquisition in detail

Frontida BioPharm has raised a total funding of $8.35M over 1 round.

Here is the list of recent funding rounds of Frontida BioPharm:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 09, 2016	7923169	Series A	5509822	7939998	2012878	7068976

Access funding benchmarks and valuations. Sign up today!

View details of Frontida BioPharm's funding rounds and investors

The founders of Frontida BioPharm is Song Li. Song Li is the CEO of Frontida BioPharm.

Here are the details of Frontida BioPharm's key team members:

Song Li: Founder & CEO of Frontida BioPharm and founder of 1 other company.

View details of Frontida BioPharm's Founder profiles and Board Members

Frontida BioPharm's employee count trend

Frontida BioPharm has 57 employees as of Mar 26. Here is Frontida BioPharm's employee count trend over the years:

Employee count trend for Frontida BioPharm

Uncover Frontida BioPharm's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Frontida BioPharm include Concord Biotech, BDR Pharmaceuticals Internationals and Almac Group. Here is the list of Top 10 competitors of Frontida BioPharm, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Concord Biotech 2000, Ahmedabad (India), Public	CDMO focused on manufacturing API	-	Quadria Capital, Helix Investments & 18 others	64/100
2nd	BDR Pharmaceuticals Internationals 2003, Mumbai (India), Late Stage	Developer and manufacturer of APIs as well as finished products	$88.2M	Multiples Alternate Asset Management, HCL Capital ... & 15 others	62/100
3rd	Almac Group 2001, Craigavon (United Kingdom), Series D	CRAMS company offering preclinical development and CDMO services, also offering companion diagnostic development	$339M	Genomic Health, Gates Foundation & 4 others	60/100
4th	Indoco Remedies 1947, Mumbai (India), Public	Provider of APIs manufacturing and formulation services	-	Baring Private Equity Partners	56/100
5th	Pharmaceutics International 1994, Hunt Valley (United States), Acquired	CDMO focused on manufacturing pharmaceutical dosage forms	$171M	Athyrium Capital Management, Signet Healthcare Partners ... & 2 others	55/100
6th	Aurobindo Pharma 1986, Hyderabad (India), Public	Provider of generic biocatalytic solutions	-	Affirma Capital, Baring Private Equity Partners ... & 4 others	55/100
7th	Seqens 2003, Ecully (France), Acquired	Provider of contract manufacturing services for small molecules & peptides	-	Ardian, Societe Generale Capital Partenaire ... & 4 others	54/100
8th	Asymchem 1995, Morrisville (United States), Public	API & Peptide CDMO, based out of China	-	Hillhouse, China Merchants Capital & 4 others	53/100
9th	Wanbury Limited 1990, Mumbai (India), Public	Manufacturer of anti-diabetic drugs	-	-	52/100
10th	Biophore 2007, Hyderabad (India), Seed	Development and manufacturing of niche pharmaceutical products for the generic industry	$2.74M	Ontario & 6 others	51/100
14th	Frontida BioPharm 2016, Exton (United States), Acquired	Contract development and manufacturing services for small molecules	$8.35M	-	39/100